Showing results (71-80 of 92) with videos related to
Sort By:
Pageof 10
Micropublication Biology|February 24, 2025
Genome sequences of three temperate actinobacteriophages from clusters FA and ASJonathan G Lawton, Alyssa D Reddy, Victoria M Herrera, et al.FEBS Letters|January 9, 1984
New potent inhibitors of angiotensin converting enzymeM R Attwood, R J Francis, C H Hassall, et al.Cancer Treatment Reports|June 1, 1986
Phase II study of ifosfamide in cervical cancerC A Meanwell, J J Mould, G Blackledge, et al.Journal of Medicinal Chemistry|January 8, 1993
Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restrictionR A Bit, P D Davis, L H Elliott, et al.Drugs Under Experimental and Clinical Research|January 1, 1991
Novel, potent and selective inhibitors of protein kinase C show oral anti-inflammatory activityJ S Nixon, J Bishop, D Bradshaw, et al.International Journal of Tissue Reactions|January 1, 1991
Potent collagenase inhibitors prevent interleukin-1-induced cartilage degradation in vitroJ S Nixon, K M Bottomley, M J Broadhurst, et al.Agents and Actions|September 1, 1992
Oral, anti-inflammatory activity of a potent, selective, protein kinase C inhibitorM J Mulqueen, D Bradshaw, P D Davis, et al.FEBS Letters|November 18, 1991
A novel conformationally restricted protein kinase C inhibitor, Ro 31-8425, inhibits human neutrophil superoxide generation by soluble, particulate and post-receptor stimuliR E Muid, M M Dale, P D Davis, et al.Journal of Medicinal Chemistry|March 20, 1992
Inhibitors of protein kinase C. 2. Substituted bisindolylmaleimides with improved potency and selectivityP D Davis, L H Elliott, W Harris, et al.Bioconjugate Chemistry|January 1, 1990
Site-directed chemical modification and cross-linking of a monoclonal antibody using equilibrium transfer alkylating cross-link reagentsF A Liberatore, R D Comeau, J M McKearin, et al.Pageof 10